The company reveals the addition of new senior team members and drugs development status.
Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, is pleased to provide a corporate update.
“2019 was an important year for Biogenum,” said Dr Choi Jun-seok, Chairman and CEO ...
